Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: A phase I/II trial

European Journal of Gastroenterology and Hepatology

Volumn 20, Issue 10, 2008, Pages 1012-1019

  Pinter, Matthias ^a   Wichlas, Martina ^a   Schmid, Katharina ^a   Plank, Christina ^b   Müller, Christian ^a   Wrba, Friedrich ^a   Peck Radosavljevic, Markus ^a,b  

^a KH Barmherzige Schwestern Wien ^*  (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Angiogenic cytokines; Antiangiogenic therapy; Hepatocellular carcinoma; Microvessel density; Thalidomide

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; ENDOSTATIN; LAXATIVE; THALIDOMIDE; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; BRADYCARDIA; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DENSITY; DISEASE COURSE; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPNEA; EVENING DOSAGE; FATIGUE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPOACUSIS; LIVER CELL CARCINOMA; LIVER FUNCTION; LOADING DRUG DOSE; MALE; MICROVASCULATURE; MUSCLE HYPOTONIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PRURITUS; RASH; SENSORY DYSFUNCTION; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR VASCULARIZATION; TUMOR VOLUME; UPREGULATION; VENOUS THROMBOEMBOLISM; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CAPILLARIES; CARCINOMA, HEPATOCELLULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDOSTATINS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; THALIDOMIDE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 53549121418     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283036740     Document Type: Article

References (47)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001 ; 94:153-156.
2. Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 2003; 21:4329-4335.
3. Bosch F. Global epidemiology of hepatocellular carcinoma. In: Okuda K, Tabor E, editors. Liver cancer. New York: Churchill Livingstone; 1997. pp. 13-28.
4. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world; global burden of disease study. Lancet 1997; 349:1 269-1276.
5. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139:817-823.
6. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40:225-235.
7. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19:329-338.
8. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10:S115-S120.
9. Llovet J, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S, et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial) [abstract]. J Clin Oncol 2007; 25:LBA1.
10. Wang TE, Kao CR, Lin SC, Chang WH, Chu CH, Lin J, et al. Salvage therapy for hepatocellular carcinoma with thalidomide. World J Gastroenterol 2004; 10:649-653.
11. Chow NH, Hsu PI, Lin XZ, Yang HB, Chan SH, Cheng KS, et al. Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. Hum Pathol 1997; 28:698-703.
12. Mise M, Arii S, Higashituji H, Furutani M, Niwano M, Harada T, et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 1996; 23:455-464.
13. Miura H, Miyazaki T, Kuroda M, Oka T, Machinami R, Kodama T, et al. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol 1997; 27:854-861.
14. Torimura T, Sata M, Ueno T, Kin M, Tsuji R, Suzaku K, et al. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 1998; 29:986-991.
15. Schwartz JD, Sung M, Schwartz M, Lehrer D, Mandeli J, Liebes L, et al. Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. Oncologist 2005; 10:718-727.
16. Poon RT, Ng IO, Lau C, Yu WC, Yang ZF, Fan ST, et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 2002; 20:1775-1785.
17. Tanigawa N, Lu C, Mitsui T, Miura S. Quantitation of sinusoid-like vessels in hepatocellular carcinoma: its clinical and prognostic significance. Hepatology 1997; 26:1216-1223.
18. Zwingenberger K, Wnendt S. Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations. J Inflamm 1995; 46:177-211.
19. Lenz W. Thalidomide and congenital abnormalities. Lancet 1961; l:45.
20. Mc Bride WG. Thalidomide and congenital abnormalities. Lancet 1961 ; II:1358.
21. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 994; 91:4082-4085.
22. Kumar S, Rajkumar SV. Thalidomide and dexamethasone: therapy for multiple myeloma. Expert Rev Anticancer Ther 2005; 5:759-766.
23. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21:16-19.
24. Motzer RJ, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, et al. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 2002; 20:302-306.
25. Stebbing J, Benson C, Eisen T, Pyle L, Smalley K, Bridle H, et al. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer 2001 ; 85:953-958.
26. Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18:2593-2602.
27. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001; 7:1888-1893.
28. Hsu C, Chen CN, Chen LT, Wu CY, Yang PM, Lai MY, et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 2003; 65:242-249.
29. Lin AY, Brophy N, Fisher GA, So S, Biggs C, Yock Tl, et al. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 2005; 103:119-125.
30. Chiou HE, Wang TE, Wang YY, Liu HW. Efficacy and safety of thalidomide in patients with hepatocellular carcinoma. World J Gastroenterol 2006; 12:6955-6960.
31. Patt YZ, Hassan MM, Lozano RD, Nooka AK, Schnirer II, Zeldis JB, et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer 2005; 103:749-755.
32. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
33. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991 ; 324:1-8.
34. The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28:751-755.
35. UNOS/OPTN policy 3.6.4.4. Available at http://www.optn.org. [Accessed 15 January 2005]
36. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62-67.
37. Yau T, Chan P, Wong H, Ng KK, Chok SH, Cheung TT, et al. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma. Oncology 2007; 72 (Suppl 1):67-71.
38. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2:727-739.
39. Richardson P, Hideshima T, Anderson K. Thalidomide: emerging role in cancer medicine. Annu Rev Med 2002; 53:629-657.
40. Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Volcker HE. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 1998; 236: 461-466.
41. Tamilarasan KP, Kolluru GK, Rajaram M, Indhumathy M, Saranya R, Chatterjee S. Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells. BMC Cell Biol 2006; 7:17.
42. McCarty MR Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. Med Hypotheses 1997; 49:123-131.
43. Yabu T, Tomimoto H, Taguchi Y, Yamaoka S, Igarashi Y, Okazaki T. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1 -phosphate. Blood 2005; 106:125-134.
44. Hannun YA, Luberto C. Ceramide in the eukaryotic stress response. Trends Cell Biol 2000; 10:73-80.
45. Ancellin N, Colmont C, Su J, Li Q, Mittereder N, Chae SS, et al. Extracellular export of sphingosine kinase-1 enzyme. Sphingosine 1-phosphate generation and the induction of angiogenic vascular maturation. J Biol Chem 2002; 277:6667-6675.
46. Hsu C, Chen CN, Chen LT, Wu CY, Hsieh FJ, Cheng AL. Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors. Radiology 2005; 235:509-516.
47. El-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Igarashi M, Yamamoto A, et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 1998; 27:1554-1562.